Diosmin
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Diosmin: From Chronic Venous Insufficiency to Amenorrhea
One-Sentence Summary
Diosmin is a flavone O-glycoside compound, clinically established as a venotonic and microcirculation-improving agent, primarily used for chronic venous insufficiency (CVI) and hemorrhoids. The TxGNN model predicts it may have potential for Amenorrhea, based on theoretical phytoestrogenic and vascular mechanisms linking flavonoid compounds to hormonal pathways. However, this direction is currently supported by no clinical trials and no published literature, placing it at the lowest evidence tier.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic venous insufficiency; hemorrhoids (venotonic agent) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 — Model prediction only; no actual studies identified |
| India Market Status | ✗ Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Diosmin (DB08995) is a flavone O-glycoside with well-established activity as a venotonic agent and microcirculation enhancer. Its primary clinical use is for chronic venous insufficiency and hemorrhoidal disease, where it acts by improving venous tone, reducing capillary permeability, and modulating lymphatic drainage.
The TxGNN model’s prediction linking Diosmin to amenorrhea appears to stem from the known overlap between flavonoid chemistry and hormonal biology. Three theoretical pathways exist: first, phytoestrogenic activity — flavonoids are known to interact weakly with estrogen receptors (ERα/ERβ), which could in principle modulate the hypothalamic-pituitary-ovarian (HPO) axis and menstrual cycling; second, aromatase modulation — some flavonoids influence CYP19A1 activity, affecting the estrogen-to-androgen ratio, though the directionality of this effect does not straightforwardly align with inducing menstruation; third, uterine blood flow improvement — Diosmin’s vasoactive properties could theoretically improve uterine perfusion in cases of functional amenorrhea, though no literature has tested this directly.
It is important to note that the high TxGNN score (0.9941) reflects topological proximity within the knowledge graph between flavonoid compounds and hormone-related pathways — not direct biological activity evidence. The mechanistic link between Diosmin and amenorrhea remains highly speculative at this stage, and no preclinical, clinical, or observational data currently supports this repurposing direction.
Clinical Trial Evidence
Currently no related clinical trials registered for Diosmin in amenorrhea.
Literature Evidence
Currently no related literature available for Diosmin in amenorrhea.
India Market Information
Diosmin currently holds no drug registrations in India. The product is not marketed domestically.
Safety Considerations
Please refer to the package insert for safety information.
(No drug-drug interaction records were identified. Key warnings and contraindications data were not available from the sources queried.)
Conclusion and Next Steps
Decision: Hold
Rationale: There is currently zero clinical or preclinical evidence supporting Diosmin’s use in amenorrhea. The TxGNN score reflects knowledge graph topology rather than direct biological proof, and the proposed mechanisms are speculative. With no registered trials, no published studies, and no India market presence, the evidence base is insufficient to justify further investment at this time.
To proceed, the following is needed:
- Preclinical mechanistic evidence: In vitro or animal studies examining Diosmin’s effect on the HPO axis, uterine blood flow, or estrogenic receptor activity in the context of amenorrhea
- MOA clarification: Retrieve full mechanism of action data from DrugBank API (currently a data gap) to better characterise phytoestrogenic potential
- Literature review expansion: Broaden search to include related flavonoids (e.g., diosmetin, hesperidin) and amenorrhea or menstrual irregularity to assess class-level evidence
- Safety package: Obtain prescribing information / package insert to complete the safety assessment before any further evaluation stages
- Regulatory pathway assessment: If preclinical evidence emerges, evaluate feasibility of market entry in India given zero existing registrations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.